
- BioPharm International, June 2023
- Volume 36
- Issue 06
- Pages: 3
Governance of Future Pandemics
COVID-19 has raised the specter of pandemic planning and the question of what can be done now to prevent future disaster.
At the G7 Summit held from May 19–21, 2023 in Hiroshima, Japan, President Biden announced a $250 million contribution, subject to Congressional notification, to the World Bank’s Pandemic Fund “to demonstrate the United States’ ongoing commitment to strengthening global health security around the world” (1). This fund was set up in September 2022, and expressions of Interest (EOI) to use funds were open in February 2023, with a closing date of May 19, 2023, which saw the fund oversubscribed by EOI by 23-fold, according to a World Bank brief on the subject (2).
To date, more than $1.66 billion has been pledged to the fund by partners, with the US government contribution of $450 million galvanizing funding from other donors. An additional $500 million was requested in President Biden’s Fiscal Year 2024 Budget, “... which will be a critical step towards addressing what the World Bank estimates is a $10 billion annual funding gap in pandemic preparedness” (1).
While the amounts involved seem small in comparison to the outsized havoc COVID-19 wrecked on world economies large and small, it is nonetheless a hopeful signal to see transnational cooperation on something that, in an interconnected world, affects everyone everywhere. But it also raises the question about how to prioritize both planning and spending to mitigate the blow of future pandemics.
What should have been in place prior to COVID-19 surfacing—and from that hard won education—should be put in place now as a consequence to what we learned. Is surveillance more useful than production capacity? Is mechanism of transmission invaluable versus manufacturing agility and capacity. These are hard questions but need answering now, not in some far-off future time zone.
References
1. USAID.
2. The World Bank.
About the author
Mike Hennessy Jr. is the President and CEO of MJH Life Sciences.
Article details
BioPharm International
Vol. 36, No. 6
June 2023
Page: 3
Citation
When referring to this article, please cite it as Hennessy, M. Governance of Future Pandemics. BioPharm International 36 (6) 2023.
Articles in this issue
over 2 years ago
Moving Closer to Dynamic Drug Developmentover 2 years ago
Pushing the Barriers in Next-Gen Antibody Developmentover 2 years ago
Pulling Out All the Stops in mAb Manufacturingover 2 years ago
Assessing Biosimilarity with Analytical Advancementsover 2 years ago
FDA Eyes New Strategies to Spur Gene Therapy Developmentover 2 years ago
Generating Benefits with Outsourced Packagingover 2 years ago
Vaccine Nationalism Escalating Riskover 2 years ago
Media for Suspension-Based Viral-Vector ManufacturingNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.